Convenient once-a-month dosing with no routine lab monitoring
Taking COSENTYX once a month for your psoriatic arthritis (PsA), with no routine lab monitoring during treatment,† helps you have fewer interruptions in your daily routine and can help provide real relief from multiple symptoms of PsA.
- To start, your doctor will either prescribe 5 weekly doses or just one dose once a month, based on what's right for you. After that, you only need to take COSENTYX once a month.† The recommended dose is 150 mg, which is taken as one injection under the skin.
- If you continue to have PsA symptoms, your rheumatologist may prescribe 300 mg (taken as two 150 mg injections).
- If you have PsA but also have moderate to severe plaque psoriasis, your rheumatologist may prescribe 300 mg (taken as two 150 mg injections).
- COSENTYX is injected with the Sensoready® Pen or a prefilled syringe.
†Before starting, get checked for tuberculosis.
‡Monthly dose equals 1 dose every 4 weeks.
If you're taking the 150-mg dose, and you continue to experience some PsA symptoms, your rheumatologist may increase your dose to 300 mg to help you feel better.
Your healthcare provider should show you how to inject COSENTYX before you use it the first time.
The COSENTYX Sensoready Pen is designed for comfortable use:
You can self-inject safely and confidently
The green indicator assures you that your injection has been completely delivered
Easy, no-button activation
Automatic 2-click technology allows you to hear when your dose starts and finishes
Designed to be easy to hold and easy to use
Learn more about how to use the Sensoready Pen and about COSENTYX in the prefilled syringe.
Find out why people are using the COSENTYX Sensoready Pen:
More than 90% of people reported no pain or reaction during or after the injection§
Nearly 9 out of 10 people reported being satisfied or very satisfied with self-injection using the Sensoready Pen§
Download this handy brochure with instructions and tips so you have them whenever you need them.
§In a study of patients with active PsA.
Very few people in a PsA clinical trial (1.6%) experienced any injection site reactions with COSENTYX‖
‖Results are from clinical trials at week 16.
"What I like about the Sensoready Pen is that it's like...so easy to use."